Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Veracyte (VCYT) Shares Issued (2016 - 2026)

Veracyte's Shares Issued history spans 14 years, with the latest figure at $3.5 million for Q4 2025.

On a quarterly basis, Shares Issued rose 7.54% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.1 million, a 29.57% decrease, with the full-year FY2025 number at $14.1 million, down 29.57% from a year prior.
Shares Issued hit $3.5 million in Q4 2025 for Veracyte, down from $5.8 million in the prior quarter.
Over the last five years, Shares Issued for VCYT hit a ceiling of $589.9 million in Q2 2021 and a floor of -$583.2 million in Q3 2021.
Historically, Shares Issued has averaged $32.3 million across 5 years, with a median of $3.0 million in 2024.
The widest YoY moves for Shares Issued: up 28390.46% in 2021, down 5866.15% in 2021.
Tracing VCYT's Shares Issued over 5 years: stood at $583.2 million in 2021, then crashed by 99.69% to $1.8 million in 2022, then dropped by 1.99% to $1.8 million in 2023, then skyrocketed by 84.2% to $3.3 million in 2024, then rose by 7.54% to $3.5 million in 2025.
Business Quant data shows Shares Issued for VCYT at $3.5 million in Q4 2025, $5.8 million in Q3 2025, and $1.8 million in Q2 2025.